Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

12.54 +1.77 (+16.43%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	8,891,910
Open	10.50
Bid (Size)	12.35 (200)
Ask (Size)	12.60 (2,000)
Prev. Close	10.77
Today's Range	10.48 - 13.04
52wk Range	1.775 - 13.04
Shares Outstanding	121,613,181
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

April 02, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Performance

YTD	+53.3%	+53.3%
1 Month	+30.1%	+30.1%
3 Month	+59.5%	+59.5%
6 Month	+124.3%	+124.3%
1 Year	+527.0%	+527.0%

More News

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Via The Motley Fool

Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib ↗

February 26, 2026

Via Chartmill

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

March 16, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

February 27, 2026

Via The Motley Fool

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

Via The Motley Fool

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

February 26, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

February 23, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Via The Motley Fool

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

February 19, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗

February 06, 2026

Via The Motley Fool

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

February 03, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Via MarketMinute

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

December 12, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

December 16, 2025

From Equity Insider

Via GlobeNewswire

Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗

December 03, 2025

Via The Motley Fool

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Via The Motley Fool

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Via TokenRing AI

Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗

November 06, 2025

Via Chartmill

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?

Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Relay Therapeutics, Inc. - Common Stock trade on?

Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?

The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market

What is the current price of Relay Therapeutics, Inc. - Common Stock?

The current price of Relay Therapeutics, Inc. - Common Stock is 12.54

When was Relay Therapeutics, Inc. - Common Stock last traded?

The last trade of Relay Therapeutics, Inc. - Common Stock was at 04/02/26 04:00 PM ET

What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?

The market capitalization of Relay Therapeutics, Inc. - Common Stock is 1.53B

How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?

Relay Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.